ArticleNature2019
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.
Erratum issued Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05655000 (A First-in-Humans Supermicrosurgical Technique for the Neonatal Thymus Transplantation), which is not on this map. Cited by 242 papers.
0numbers the graph read from it
0cells of the map it votes in
242citing papers in PubMed
18.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A First-in-Humans Supermicrosurgical Technique for the Neonatal Thymus Transplantation
Who cites it
242 citing papers in PubMed, 375 citations in OpenAlex.
- Recent advances of cell therapies for AML/MDS: exploring the therapeutic potential of innate immune cells in AML/MDS.International journal of hematology · 2026Review
- Neutrophil extracellular traps promote liver metastasis by impairing NK cell-dependent tumor surveillance via CCDC25.Nature communications · 2026Article
- Sample Source and Cryopreservation Affect Flow-Cytometric Profiling of Immune-Escape-Related Markers on AML Blasts.Cancers · 2026Article
- Induced Pluripotent Stem Cell-Derived NK Cells as an Off-the-Shelf Platform for Cancer Immunotherapy: Opportunities, Challenges, and Clinical Translation.Stem cell reviews and reports · 2026Review
- Ex vivo evaluation of Newcastle disease virus to enhance natural killer cell function against acute myeloid leukemia cells.Scientific reports · 2026Article
- Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy.Annals of hematology · 2026Review
- Disrupting USP14-mediated PARP1 dynamics reinstates MIC-A/B-driven antigen-independent CD8Science advances · 2026Article
- The tumor microenvironment in hematologic malignancies: immune evasion, metabolic reprogramming, and therapeutic resistance.Blood science (Baltimore, Md.) · 2026Review
- Targeting NKG2DLs with an ADCC enhanced fusion protein for induction of NK cell reactivity against ovarian cancer.Journal of ovarian research · 2026Article
- Next-generation CAR-T therapy for acute myeloid leukemia: bridging innovation with clinical translation.Annals of hematology · 2026Review
- Immune-tumor cell ligand-receptor axes driving metabolic reprogramming and therapeutic resistance in cancer.Frontiers in immunology · 2026Review
- Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease.Frontiers in oncology · 2026Review
- Augmented myeloablative conditioning with olaparib in allogeneic hematopoietic stem cell transplantation for relapsed/refractory RUNX1::RUNX1T1-positive acute myeloid leukemia.Frontiers in oncology · 2026Article
- Sequential nasal and mammary myeloid sarcoma with a 6-year latency: a case report and literature review.Frontiers in medicine · 2026Article
- Targeting innate immunity in cancer: mechanistic foundations, therapeutic vaccination, and clinical translation.Frontiers in immunology · 2026Review
- The resilient subset: cancer stem cells at the core of immunotherapy resistance.Immunotherapy advances · 2026Review
- Leveraging the heterogeneity of the NK cell repertoire for the development of immunotherapies for acute leukemia.Journal of translational medicine · 2025Review
- Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell-mediated lysis and express targetable antigens.Blood neoplasia · 2025Article
- The systemic costs of hematopoietic stem cell aging.Development (Cambridge, England) · 2025Review
- The bispecific innate cell engager AFM28 eliminates CD123Nature communications · 2025Article
182 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
27 authors at 13 institutions in 3 countries.
Anna M Paczulla *Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Kathrin Rothfelder *Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Tuebingen, Germany.
Simon Raffel *Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
Martina KonantzDepartment of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Julia SteinbacherClinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Tuebingen, Germany.
Hui WangDepartment of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Claudia TandlerClinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Tuebingen, Germany.
Marcelle MbargaDepartment of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Thorsten SchaeferDepartment of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Mattia FalconeHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
Eva NievergallHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
Daniela DörfelDepartment of Internal Medicine II, Hematology and Oncology, Eberhard-Karls University, Tuebingen, Germany.
Pauline HannsDepartment of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Jakob R PasswegDivision of Clinical Hematology, University Hospital Basel, Basel, Switzerland.
Christoph LutzDepartment of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Juerg SchwallerDepartment of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Robert ZeiserDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, Freiburg, Germany.
Bruce R BlazarDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN, USA.
Michael A CaligiuriHematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, CA, USA.
Stephan DirnhoferInstitute for Pathology & Medical Genetics, University Hospital Basel, Basel, Switzerland.
Pontus LundbergDiagnostic Hematology, Department of Laboratory Medicine, University Hospital Basel, Basel, Switzerland.
Lothar KanzDepartment of Internal Medicine II, Hematology and Oncology, Eberhard-Karls University, Tuebingen, Germany.
Leticia Quintanilla-MartinezInstitute for Pathology, University of Tuebingen, Tuebingen, Germany.
Alexander SteinleInstitute for Molecular Medicine, Goethe University, Frankfurt am Main, Germany.
Andreas TrumppHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
Helmut R SalihClinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Tuebingen, Germany. helmut.salih@med.uni-tuebingen.de.
Claudia LengerkeDepartment of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
University Hospital of Basel · CHUniversity of Tübingen · DEUniversity of Basel · CHGerman Cancer Research Center · DEHeidelberg University · DEBeckman Research InstituteDeutschen Konsortium für Translationale Krebsforschung · DEGoethe University Frankfurt · DEHeidelberg Institute for Stem Cell Technology and Experimental Medicine · DEUniversity Children’s Hospital Basel · CHUniversity Hospital Heidelberg · DEUniversity of Freiburg · DEUniversity of Minnesota · US
Funding
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI J SUNIL RAO · 1995 to 2026
$48.2MHuman natural killer cells: Advancing biology and clinical applicationsR35CA210087 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL A CALIGIURI · 2017 to 2026
$8.3MT-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4MNCI NIH HHS P01 CA065493NCI NIH HHS R35 CA210087NHLBI NIH HHS R01 HL056067Swiss National Science Foundation 179239
Abstract
Patients with acute myeloid leukaemia (AML) often achieve remission after therapy, but subsequently die of relapse
Indexed as
Immune EvasionTumor EscapeAnimalsAntigens, CD34Disease Models, AnimalDrug Resistance, NeoplasmFemaleHumansKiller Cells, NaturalLeukemia, Myeloid, AcuteLigandsMaleMiceNeoplastic Stem CellsNK Cell Lectin-Like Receptor Subfamily KPoly (ADP-Ribose) Polymerase-1Antigens, CD34KLRK1 protein, humanLigandsNK Cell Lectin-Like Receptor Subfamily KPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05655000ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.